Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK

被引:0
作者
Rothnie, Kieran J. [1 ,7 ]
Numbere, Beade [1 ]
Gelwicks, Steven [2 ]
Lu, Yifei [1 ,3 ]
Sharma, Raj [4 ]
Compton, Chris [4 ]
Ismaila, Afisi S. [2 ,5 ]
Quint, Jennifer K. [6 ]
机构
[1] GSK, Value Evidence & Outcomes, R&D Global Med, London, England
[2] GSK, Value Evidence & Outcomes, R&D Global Med, Collegeville, PA USA
[3] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA
[4] GSK, Global Med, London, England
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[6] Imperial Coll London, Natl Heart & Lung Inst, London, England
[7] GSK, Value Evidence & Outcomes, R&D Global Med, 980 Great West Rd, Brentford TW8 9GS, Middlesex, England
来源
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2023年 / 18卷
关键词
COPD; CPRD; exacerbation; GOLD A/B; risk factor; UK; OBSTRUCTIVE PULMONARY-DISEASE; HEALTH-CARE; PREDICTION; OUTCOMES;
D O I
10.2147/COPD.S413947
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: Risk factors for exacerbations of chronic obstructive pulmonary disease (COPD) have been previously characterized for patients with more severe cases of COPD. It is unclear how the risk of first exacerbation may best be identified in patients with less severe disease. This study investigated risk factors for first exacerbation among English patients with COPD classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A or B. Patients and Methods: A retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) AURUM linked to Hospital Episode Statistics. Patients with COPD aged >= 35 years and classified as GOLD group A or B (2020 criteria) from January 2013-December 2019 were eligible. Patients were required to have 24 months history in CPRD (baseline). Two cohorts were defined: cohort 1 included patients with no severe exacerbations during baseline; cohort 2 included patients with no moderate or severe exacerbations during baseline. Risk factors associated with severe, or combined moderate and severe exacerbation were examined for up to 5 years of follow-up. Results: Overall, 194,948 patients were included in cohort 1 (mean age 66.2 years; 55.2% male), and 148,396 patients in cohort 2 (mean age 66.1 years; 56.6% male). Identified risk factors for exacerbation (and associated 1-year absolute risk of severe, or combined moderate and severe exacerbation, respectively) included: Medical Research Council dyspnea scale score (15.9%/28.4%); COPD Assessment Test score (9.6%/25.3%); GOLD grade of airflow limitation (forced expiratory volume in 1 second % predicted; 13.6%/27.5%); and lung cancer (8.1%/23.6%). After adjustment for risk factors, these factors remained independently associated with severe exacerbation at 1, 3, and 5 years of follow-up. Conclusion: The identified risk factors may aid physicians in the early recognition of patients with COPD classified as GOLD group A or B at risk of first exacerbation.
引用
收藏
页码:2673 / 2685
页数:13
相关论文
共 26 条
  • [1] The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study
    Adibi, Amin
    Sin, Don D.
    Safari, Abdollah
    Johnson, Kate M.
    Aaron, Shawn D.
    FitzGerald, J. Mark
    Sadatsafavi, Mohsen
    [J]. LANCET RESPIRATORY MEDICINE, 2020, 8 (10) : 1013 - 1021
  • [2] Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort
    Agusti, Alvar
    Edwards, Lisa D.
    Celli, Bartolome
    MacNee, William
    Calverley, Peter M. A.
    Muellerova, Hana
    Lomas, David A.
    Wouters, Emiel
    Bakke, Per
    Rennard, Steve
    Crim, Courtney
    Miller, Bruce E.
    Coxson, Harvey O.
    Yates, Julie C.
    Tal-Singer, Ruth
    Vestbo, Jorgen
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (03) : 636 - 646
  • [3] [Anonymous], 2022, Chronic obstructive pulmonary disease (COPD) statistics
  • [4] blf, 2016, British lung foundation the battle for breath-the impact of lung disease in the UK
  • [5] Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study
    Gedebjerg, Anne Y.
    Szepligeti, Szimonetta Komjathine
    Wackerhausen, Laura-Maria Holm
    Horvath-Puho, Erzsebet
    Dahl, Ronald
    Hansen, Jens Georg
    Sorensen, Henrik Toft
    Norgaard, Mette
    Lange, Peter
    Thomsen, Reimar Wernich
    [J]. LANCET RESPIRATORY MEDICINE, 2018, 6 (03) : 204 - 212
  • [6] GOLD Global Initiative for Chronic Obstructive Lung Disease, 2017, PNEUMOLOGIE
  • [7] goldcopd, 2022, GOLD Global Initiative for Chronic Obstructive Lung Disease-global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2023 report
  • [8] Neither baseline blood nor sputum eosinophils predict future exacerbations in the SPIROMICS cohort
    Hastie, A.
    Quibrera, P. M.
    Couper, D.
    Alexis, N.
    Barjaktarevic, I
    Curtis, J.
    Bleecker, E.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [9] Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease.
    Hurst, John R.
    Vestbo, Jorgen
    Anzueto, Antonio
    Locantore, Nicholas
    Muellerova, Hana
    Tal-Singer, Ruth
    Miller, Bruce
    Lomas, David A.
    Agusti, Alvar
    MacNee, William
    Calverley, Peter
    Rennard, Stephen
    Wouters, Emiel F. M.
    Wedzicha, Jadwiga A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12) : 1128 - 1138
  • [10] Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review
    Iheanacho, Ike
    Zhang, Shiyuan
    King, Denise
    Rizzo, Maria
    Ismaila, Afisi S.
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 439 - 460